# Pierre Ronco

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/pierre-ronco/

## Facts

| Field | Value |
| --- | --- |
| Citations | 29,893 |
| Field | Renal Diseases and Glomerulopathies |
| h-index | 87 |
| i10-index | 315 |
| Last Known Institution | Inserm |
| OpenAlex ID | https://openalex.org/A5014081829 |
| ORCID iD | 0000-0002-0280-6900 |
| Works | 770 |

## Researcher papers

Showing 12 of 17.

- [KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases](https://scholariq.org/papers/kdigo-2021-clinical-practice-guideline-for-the-management-of-glomerular-diseases/)
- [Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis](https://scholariq.org/papers/definition-of-organ-involvement-and-treatment-response-in-immunoglobulin-light/)
- [Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases](https://scholariq.org/papers/executive-summary-of-the-kdigo-2021-guideline-for-the-management-of-glomerular/)
- [Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference](https://scholariq.org/papers/nomenclature-for-kidney-function-and-disease-report-of-a-kidney-disease/)
- [Antenatal Membranous Glomerulonephritis Due to Anti–Neutral Endopeptidase Antibodies](https://scholariq.org/papers/antenatal-membranous-glomerulonephritis-due-to-anti-neutral-endopeptidase/)
- [High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis](https://scholariq.org/papers/high-dose-melphalan-versus-melphalan-plus-dexamethasone-for-al-amyloidosis/)
- [Risk HLA-DQA1 and PLA <sub>2</sub> R1 Alleles in Idiopathic Membranous Nephropathy](https://scholariq.org/papers/risk-hla-dqa1-and-pla-sub-2-sub-r1-alleles-in-idiopathic-membranous-nephropathy/)
- [Membranous nephropathy](https://scholariq.org/papers/membranous-nephropathy/)
- [Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up](https://scholariq.org/papers/rituximab-for-severe-membranous-nephropathy-a-6-month-trial-with-extended-follow/)
- [Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy](https://scholariq.org/papers/anti-phospholipase-a2-receptor-antibody-titer-predicts-post-rituximab-outcome-of/)
- [Antiphospholipase A2 Receptor Antibody Titer and Subclass in Idiopathic Membranous Nephropathy](https://scholariq.org/papers/antiphospholipase-a2-receptor-antibody-titer-and-subclass-in-idiopathic/)
- [Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN](https://scholariq.org/papers/mayo-clinic-renal-pathology-society-consensus-report-on-pathologic/)

## Researcher topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Amyloidosis: Diagnosis, Treatment, Outcomes](https://scholariq.org/topics/amyloidosis-diagnosis-treatment-outcomes/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)

## Researcher university

- [Inserm](https://scholariq.org/institutions/inserm/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.